Literature DB >> 11704647

Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.

G Minotti1, M Parlani, E Salvatorelli, P Menna, A Cipollone, F Animati, C A Maggi, S Manzini.   

Abstract

1. The anticancer anthracycline doxorubicin (DOX) causes cardiotoxicity. Enzymatic reduction of a side chain carbonyl group converts DOX to a secondary alcohol metabolite that has been implicated in cardiotoxicity. We therefore monitored negative inotropism, assessed as inhibition of post-rest contractions, in rat right ventricle strips exposed to DOX or to analogues forming fewer amounts of their alcohol metabolites (epirubicin, EPI, and the novel disaccharide anthracycline MEN 10755). 2. Thirty microM EPI exhibited higher uptake than equimolar DOX, but formed comparable amounts of alcohol metabolite due to its resistance to carbonyl reduction. MEN 10755 exhibited also an impaired uptake, and consequently formed the lowest levels of alcohol metabolite. Accordingly, DOX and EPI inhibited post-rest contractions by approximately 40-50%, whereas MEN 10755 inhibited by approximately 6%. 3. One hundred microM EPI exhibited the same uptake as equimolar DOX, but formed approximately 50% less alcohol metabolite. One hundred microM MEN 10755 still exhibited the lowest uptake, forming approximately 60% less alcohol metabolite than EPI. Under these conditions DOX inhibited post-rest contractions by 88%. EPI and MEN 10755 were approximately 18% (P<0.05) or approximately 80% (P<0.001) less inhibitory than DOX, respectively. 4. The negative inotropism of 30-100 microM DOX, EPI, or MEN 10755 correlated with cellular levels of both alcohol metabolites (r=0.88, P<0.0001) and carbonyl anthracyclines (r=0.79, P<0.0001). Nonetheless, multiple comparisons showed that alcohol metabolites were approximately 20-40 times more effective than carbonyl anthracyclines in inhibiting contractility. The negative inotropism of MEN 10755 was therefore increased by chemical procedures, like side chain valeryl esterification, that facilitated its uptake and conversion to alcohol metabolite but not its retention in a carbonyl form. 5. These results demonstrate that secondary alcohol metabolites are important mediators of cardiotoxicity. A combination of reduced uptake and limited conversion to alcohol metabolite formation might therefore render MEN 10755 more cardiac tolerable than DOX and EPI.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704647      PMCID: PMC1573059          DOI: 10.1038/sj.bjp.0704369

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice.

Authors:  O Gonzalez-Paz; D Polizzi; M De Cesare; F Zunino; M Bigioni; C A Maggi; S Manzini; G Pratesi
Journal:  Eur J Cancer       Date:  2001-02       Impact factor: 9.162

2.  Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.

Authors:  K Behnia; M Boroujerdi
Journal:  J Pharm Pharmacol       Date:  1999-11       Impact factor: 3.765

3.  Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart.

Authors:  R Zucchi; G Yu; S Ghelardoni; F Ronca; S Ronca-Testoni
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 4.  Flavonoids as antioxidants.

Authors:  P G Pietta
Journal:  J Nat Prod       Date:  2000-07       Impact factor: 4.050

5.  Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.

Authors:  S Licata; A Saponiero; A Mordente; G Minotti
Journal:  Chem Res Toxicol       Date:  2000-05       Impact factor: 3.739

6.  Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.

Authors:  G Minotti; S Licata; A Saponiero; P Menna; A M Calafiore; G Di Giammarco; G Liberi; F Animati; A Cipollone; S Manzini; C A Maggi
Journal:  Chem Res Toxicol       Date:  2000-12       Impact factor: 3.739

7.  Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.

Authors:  G L Forrest; B Gonzalez; W Tseng; X Li; J Mann
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

8.  Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction.

Authors:  W Ax; M Soldan; L Koch; E Maser
Journal:  Biochem Pharmacol       Date:  2000-02-01       Impact factor: 5.858

Review 9.  Role of iron in anthracycline cardiotoxicity: new tunes for an old song?

Authors:  G Minotti; G Cairo; E Monti
Journal:  FASEB J       Date:  1999-02       Impact factor: 5.191

10.  Effect of barbiturates on hydroxyl radicals, lipid peroxidation, and hypoxic cell death in human NT2-N neurons.

Authors:  R Almaas; O D Saugstad; D Pleasure; T Rootwelt
Journal:  Anesthesiology       Date:  2000-03       Impact factor: 7.892

View more
  5 in total

1.  A novel method to detect intracellular metabolite alterations in MCF-7 cells by doxorubicin induced cell death.

Authors:  Ajay Kumar; Sheetal Patel; Devyani Bhatkar; Sachin C Sarode; Nilesh Kumar Sharma
Journal:  Metabolomics       Date:  2021-01-03       Impact factor: 4.290

2.  Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.

Authors:  Anselm Morell; Youssif Budagaga; Dimitrios Vagiannis; Yu Zhang; Lenka Laštovičková; Eva Novotná; Andrew Haddad; Melodie Haddad; Ramon Portillo; Jakub Hofman; Vladimír Wsól
Journal:  Arch Toxicol       Date:  2022-08-16       Impact factor: 6.168

3.  Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Authors:  Giuseppe Sacco; Rossella Giampietro; Emanuela Salvatorelli; Pierantonio Menna; Nicoletta Bertani; Gallia Graiani; Fabio Animati; Cristina Goso; Carlo A Maggi; Stefano Manzini; Giorgio Minotti
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

4.  Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.

Authors:  Carrie C Hoefer; Rachael Hageman Blair; Javier G Blanco
Journal:  J Pharm Sci       Date:  2016-04-23       Impact factor: 3.534

Review 5.  Iron-regulatory proteins: molecular biology and pathophysiological implications.

Authors:  Gaetano Cairo; Stefania Recalcati
Journal:  Expert Rev Mol Med       Date:  2007-12-05       Impact factor: 5.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.